Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14843212 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDMAPTCYP1A2CYP2C9 | |
| SCHEMBL7414841 | 0.76 | HPGD (0.69) | SMN1; SMN2HPGDMAPTCYP1A2CYP2C9 | |
| SCHEMBL7784771 | 0.75 | PARP1 (0.50) | SMN1; SMN2HPGDTNKSPARP1WNT3A | |
| SCHEMBL9879495 | 0.74 | ALDH1A1 (0.41) | SMN1; SMN2HPGDTNKSPARP1WNT3A | |
| SCHEMBL14852653 | 0.69 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDPARP1MAPTCYP1A2 | |
| SCHEMBL14842749 | 0.66 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDMAPTCYP1A2CYP2C9 | |
| SCHEMBL9385093 | 0.62 | PDE4B (0.31) | — | |
| SCHEMBL26975119 | 0.61 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2LMNAKDM4CNPSR1 | |
| SCHEMBL14852714 | 0.60 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDMAPTCYP1A2CYP2C9 | |
| SCHEMBL10991513 | 0.60 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDMAPTCYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-2763985-B1 | {(4-(4-MORPHOLINO-DIHYDROTHIENO[3,4-D]PYRIMIDIN-2-YL)ARYL}UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-2763985-B1 | {(4-(4-MORPHOLINO-DIHYDROTHIENO[3,4-D]PYRIMIDIN-2-YL)ARYL}UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2763985-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050508-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050508-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, CCNT1 | SMN1; SMN2 2407/4885HPGD 3849/4885TNKS 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.